Virology

HOT RECEPTION: From left, NIAID investigators Edward Berger, Paul Kennedy, Christopher Broder, and Yu Feng helped to break open the field of HIV coreceptor research with their discovery of fusin. Comments by Edward A. Berger, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases Within three years after the discovery of HIV as the causative agent of AIDS, scientists identified the CD4 molecule as the primary cellular receptor for HIV. They believed the virus ent

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Within three years after the discovery of HIV as the causative agent of AIDS, scientists identified the CD4 molecule as the primary cellular receptor for HIV. They believed the virus entered target cells by an initial binding event between the envelope glycoprotein (Env) molecules on the viral membrane and CD4 molecules on the target cell surface. Yet as early as 1986, it became clear that the Env-CD4 interaction was not sufficient to promote the fusion reaction that results in HIV infection. Research teams searched for a coreceptor for roughly a decade. In 1996, a research team from the National Institute of Allergy and Infectious Diseases (NIAID) led by Edward A. Berger, chief of the molecular structure section, Laboratory of Viral Diseases, discovered the HIV coreceptor they dubbed "fusin" (later CXCR4); this molecule allowed HIV infection in CD4-expressing nonhuman cells through fusion with Env-mediated cells, and it blocked infection and fusion ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies